Top pharma companies by sales loss due to patent loss until 2018

Published by
Matej Mikulic,
Sep 12, 2017
This statistic displays the leading pharmaceutical companies based on potential sales loss due to patent expirations until year-end 2018. According to the source, 30 percent of Astra Zeneca's 2015 revenue is at risk due to drugs losing patents by the end of 2018.

Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

January 2017

Region

Worldwide

Survey time period

as of January 2017

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Generics and biosimilars "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Generics and biosimilars

Global overview

4

Top companies

4

U.S. market

6

Patent expiration

6

Savings

7

Biosimilars

7

Further related statistics

14

Further Content: You might find this interesting as well

Statistics

Topics

SanofiGlobal pharmaceutical industryTop pharmaceutical drugsPfizerNovartis
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.